pDNA is critical to many advanced and emerging therapies, including cell and gene therapies and mRNA vaccines, as it is the key starting material used in these therapies. Since the quality of the pDNA is vital to the success of these programs, biologics organizations must make decisions around pDNA design early in the development process. Further, to ensure these fragile products move from development to manufacturing without a hitch, they must choose the right partner wisely.

This article details the key parameters biotechs can use to select the right CDMO for manufacturing pDNA and biologics safely and efficiently.

Global CDMO Syngene has a proven track record in providing end-to-end solutions in biologics manufacturing, including producing pDNA of high purity and yield. With strong experience in microbial fermentation and platform processes, Syngene offers cost-effective high-quality pDNA, including research grade, GMP-like grade, and GMP grade pDNA. Its full-scope production capabilities make it suitable for most research, development, and GMP needs.